David A. Ramsay has been appointed chief financial officer at Halozyme Therapeutics, Inc. Mr. Ramsay most recently served as vice president of corporate development.
Mr. Ramsay joined the company in 2003 and his accomplishments include spearheading the process of taking Halozyme public in 2004, negotiating equity investments made by Roche and Baxter, negotiating and signing the Baxter Hylenex collaboration, and ultimately leading the effort to reintroduce Hylenex to the market in late 2011. Prior to Halozyme, he served in various financial roles including vice president, chief financial officer of Lathian Systems, and vice president, treasurer of ICN Pharmaceuticals, now Valeant Pharmaceuticals.
"With his established financial management experience and his recent commercial and operational experience gained by working in our commercial group for the last four years, David brings strong assets to advance the company, manage financial growth and deliver value for our shareholders," said Gregory I. Frost, Ph.D., president and chief executive officer at Halozyme. Mr. Ramsay replaces Kurt Gustafson who is leaving the company to pursue other opportunities. "We wish Kurt the best and sincerely thank him for his years of service helping to build our business.”